FOS and prostate carcinoma: Interestingly, three patients with functional MAP kinase pathway 5′-UTR mutations to FOS, FGF7, and MECOM that were predicted to increase signaling by PLUMAGE demonstrated upregulation of a RAS-driven prostate cancer MAP kinase pathway gene signature45 (Fig. 7b).